Sigilon Therapeutics, Inc.

Nasdaq : SGTX

Phase 1/2 biotech developing allogeneic therapies for hemophilia A and diabetes.

  • Filed 13-11-2020
  • Set Terms --
  • IPO Date 04-12-2020
  • Lock Up 05-03-2021
Текущая цена
3.14 $
Текущая доходность
-82.56 %
Доходность за 1 день торгов
93.22 %
Доходность по итогам
Lock up периода
28.78 %
Рейтинг от IPO.one:
Дата IPO
04-12-2020
Объем размещения
7 000 000
Размер сделки ($M)
126
Диапазон цены
17-19 $
Цена IPO
18 $
Lock Up
05-03-2021
Год основания
2015
Головной офис
Cambridge, MA
Веб сайт
Юристы
Latham & Watkins Ropes & Gray
Аудитор
PwC
Андеррайтер
Morgan Stanley

Описание компании

We are a clinical-stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. We have developed our Shielded Living Therapeutics, or SLTx, platform, which combines advanced cell engineering with cutting-edge innovations in biocompatible materials and enables our product candidates to produce a wide range of therapeutic molecules that may be missing or deficient, such as proteins, antibodies and hormones. We are designing our product candidates to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient's genes or immunosuppression. Our lead product candidate, SIG-001, is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A by continuously secreting human FVIII. We received acceptance of our IND submission in the United States in August 2020 and our CTA in the United Kingdom in May 2020. We have initiated our Phase 1/2 clinical study of SIG-001 in Hemophilia A, with the first patient dosed in October 2020.